First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

B. Douglas Smith, M.D., Baltimore

Mayo Clinic, Jacksonville

Uab Comprehensive Cancer Center, Birmingham

Northwestern University Feinberg School Of Medicine, Chicago

University Of Kansas Cancer Center And Medical Pavillion, Westwood

The University Of Texas Md Anderson Cancer Center, Houston

Usc - Norris Comprehensive Cancer Center And Hospital, Los Angeles

Ucla-Division Of Hematology/Oncology, Los Angeles

Uc San Diego Moores Cancer Center, La Jolla

University Of Washington School Of Medicine, Seattle

Dana-Farber Cancer Inst, Boston